Skip to main content
Viva Biotech Holdings logo

Viva Biotech Holdings — Investor Relations & Filings

Ticker · 1873 LEI · 300300VJBVYQ6XJUKY15 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 473 across all filing types
Latest filing 2026-04-22 Environmental & Social …
Country KY Cayman Islands
Listing HKEX 1873

About Viva Biotech Holdings

http://www.vivabiotech.com

Viva Biotech Holdings provides comprehensive, integrated drug discovery, development, and manufacturing services (CRO/CDMO) to global biotechnology and pharmaceutical clients. The company operates a leading Structure-Based Drug Discovery (SBDD) platform, supporting innovative drug programs from early-stage preclinical research through to commercialization. Core services encompass protein expression and structure determination, hits screening, therapeutic antibody discovery, computer-aided drug design (CADD), medicinal chemistry, custom synthesis, and ADME/PK studies. This one-stop service model facilitates the entire drug development lifecycle for its worldwide customer base.

Recent filings

Filing Released Lang Actions
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 1% confidence The document is titled "2025 Environmental, Social and Governance Report" and contains extensive sections on ESG strategies, governance structure, environmental protection measures, social responsibility initiatives, and ESG performance metrics. It follows the HKEX ESG Reporting Code and discloses the Group’s ESG performance for the year. This matches the definition for an Environmental & Social Information report (Code: SR).
2026-04-22 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a “Form of Proxy” for the Annual General Meeting, used to solicit shareholder votes on specified resolutions (e.g., election of directors, approval of financial statements, share allotment mandates). This is not the meeting minutes or results, nor an annual report, but rather proxy solicitation material sent to shareholders to request votes. Therefore it fits the Proxy Solicitation & Information Statement category (PSI).
2026-04-22 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal Notice of Annual General Meeting sent to shareholders, containing the date/time/place of the AGM, the full set of resolutions to be voted on (ordinary resolutions regarding financial statements, director re‐elections, share issuance and buyback mandates), proxy appointment instructions, record dates, and explanatory notes. It is not the AGM presentations themselves nor a full financial report but is clearly the notice/proxy materials to solicit votes for the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI).
2026-04-22 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a shareholder circular issued ahead of the Annual General Meeting, containing detailed proposals (director re-elections; auditor re-appointment; share issue/repurchase mandates), explanatory notes, the notice of AGM, and the proxy form for voting. It is sent to shareholders to provide information and solicit proxies for voting, fitting the definition of a Proxy Solicitation & Information Statement rather than the AGM presentation materials or the final annual report.
2026-04-22 English
2025 Annual Report
Annual Report Classification · 1% confidence The document is clearly identified as the '2025 ANNUAL REPORT' for Viva Biotech Holdings. It contains comprehensive financial statements, management discussion and analysis, auditor's reports, and corporate governance information, which are the defining characteristics of an Annual Report (10-K equivalent for non-US jurisdictions). FY 2025
2026-04-22 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a monthly return (Form FF301) filed with the Hong Kong Stock Exchange under Chapter 19B of the Listing Rules, detailing share capital movements, share option data, and public float confirmations for the month ended 31 March 2026. It is not an annual or interim report, earnings release, management discussion, or investor presentation; rather it is a routine regulatory submission. No other more specific category applies, so it falls under the general “Regulatory Filings” category.
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.